The COVID-19 pandemic impacted nearly every aspect of the cell and gene therapy supply chain. That required companies throughout the cell and gene therapy industry to pivot quickly to continue to deliver for patients. Be The Match BioTherapies® was no exception.
Travel disruptions caused by COVID-19 have meant little more than delayed holidays or missed work meetings for most of us. They’re inconveniences, but hardly life-threatening challenges. But for patients who depend on cell therapies to provide potentially curative treatments, the pandemic’s canceled flights and closed borders have posed a real threat to their wellbeing. In…
There is no question the COVID-19 pandemic has disrupted cell therapy logistics like never before. Supply chain challenges are no longer the exception, but the norm. So how can companies overcome autologous cell therapy logistics challenges to deliver time-sensitive source material and manufactured therapies on time? It’s not easy in our current environment, but it…
Updated March 27, 2020 (original story follows) Editor’s note: It’s been just over one month since we first shared how established relationships have helped our organization navigate the impacts of the coronavirus on the cell therapy supply chain. Since then, much has changed. Just a few days after we posted the story, reports from Italy…
A well-designed cell and gene therapy supply chain is critical to patient care. Managing the cell therapy supply chain is a mission-critical industry skill. Yet, no matter how well designed your supply chain is, human-based therapies are subject to variability at each stage of delivery. At Be The Match BioTherapies®, we make sure our team…
Cell therapies represent some of the most logistically complex treatments ever created, with quality and viability dependent on seamless coordination across multiple steps. With the first CAR-T therapies now approved, and more companies entering this new terrain, managing the cell therapy supply chain has become a mission-critical industry skill. We asked two supply chain experts…